BMC Cancer (Nov 2018)

Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia

  • Luca Bertamini,
  • Jacopo Nanni,
  • Giovanni Marconi,
  • Mariachiara Abbenante,
  • Valentina Robustelli,
  • Francesco Bacci,
  • Antonella Matti,
  • Stefania Paolini,
  • Chiara Sartor,
  • Silvia Lo Monaco,
  • Maria Chiara Fontana,
  • Stefano De Polo,
  • Michele Cavo,
  • Antonio Curti,
  • Giovanni Martinelli,
  • Cristina Papayannidis

DOI
https://doi.org/10.1186/s12885-018-5026-x
Journal volume & issue
Vol. 18, no. 1
pp. 1 – 5

Abstract

Read online

Abstract Background Extramedullary involvement of B-cell Acute Lymphoblastic Leukemia (EM-ALL) is a rare occurrence, characterized by dismal outcome and the absence of a defined and shared therapeutic approach. In the landscape of innovative compounds, inotuzumab ozogamicin (IO) is a promising drug, whose mechanism of action relies on the killing of CD22 positive leukemic cells, through the delivery, after cell binding, of a molecule of calicheamicin. Case presentation We report two cases of CD22 positive relapsed EM-ALL treated with IO, obtained as compassionate use. Case 1, a 66 years old woman, affected by Philadelphia (Ph) negative B-ALL, relapsed with extramedullary involvement after 6 standard chemotherapy courses, who reached a complete metabolic response with IO treatment. Case 2, a 67 years old man with Ph positive B-ALL, initially treated with ponatinib, a third generation tyrosine-kinase inhibitor (TKI), obtaining a prolonged deep molecular remission. Nevertheless, for skin relapse during TKI treatment, the patient received local radiotherapy and, shortly after, standard chemotherapy, as multiple abdominal sites of relapse were detected too, with no response. The patient then received IO, obtained as compassionate use, with a good metabolic response. Conclusions These two cases suggest a possible key role of IO in the setting of advanced CD22 positive ALL, and underline its potential activity also in patients with EM involvement, relapsed after or refractory to conventional chemotherapy. Despite the well known hepatotoxic effect of the compound (Sinusoid Occlusive Syndrome), neither of them had such adverse event, moreover the second patient safely underwent allogeneic bone marrow transplantation.

Keywords